| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Feb 2025 | 4 Feb 2025 |
| SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Tuesday February 11 2025 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2024 Pursuant to Regulation 30 and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its Meeting held today i.e., February 11, 2025, upon the recommendation of the Audit Committee, has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 11/02/2025) | ||
| Board Meeting | 13 Nov 2024 | 6 Nov 2024 |
| SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday November 13 2024 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. Q2FY25 Results (As per BSE Announcement Dated on 13/11/2024) | ||
| Board Meeting | 26 Sep 2024 | 26 Sep 2024 |
| We wish to inform you that Board of Directors of the Company, at their meeting held today (i.e. September 26, 2024) | ||
| Board Meeting | 14 Aug 2024 | 9 Aug 2024 |
| SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday August 14 2024 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30 2024. Sequent Result Q1 FY 2024-25 (As Per Bse Announcement Dated on 14.08.2024) | ||
| Board Meeting | 15 May 2024 | 8 May 2024 |
| SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday May 15 2024 inter alia to: 1. Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024. 2. Consider dividend for the year ended March 31 2024 if any. Audited standalone and Consolidated Financial Results for the quarter and Year ended March 31, 2024. The Board has not recommended any dividend for F.Y. 2023-24. Audited standalone and Consolidated Financial Results for the quarter and Year ended March 31, 2024 1. Audited Consolidated Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024 with an unmodified opinion. 3. The Board has not recommended any dividend for F.Y. 2023-24. (As Per BSE Announcement Dated on: 15/05/2024) | ||
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
